Photo from wikipedia
We read with great interest the study by Singh and Cleveland1 that investigated the risk of hypersensitivity reactions (HRs) with allopurinol and febuxostat using Medicare claims data. These authors analysed… Click to show full abstract
We read with great interest the study by Singh and Cleveland1 that investigated the risk of hypersensitivity reactions (HRs) with allopurinol and febuxostat using Medicare claims data. These authors analysed a national cohort in the 5% Medicare beneficiary sample randomised from 2006 to 2012 of adults older than 65 years who experienced a new treatment episode with allopurinol, febuxostat or colchicine. They reported the following incidence rates for HRs: allopurinol, 23.9; febuxostat, 30.5; and colchicine, 25.7 cases per 1000 person-years. Combination treatments of febuxostat+colchicine, allopurinol+colchicine and febuxostat+colchicine+allopurinol increased the incidence of HRs …
Journal Title: Annals of the Rheumatic Diseases
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!